Centogene
Centogene is a Rostock-based, PE-owned multiomic genetic diagnostics company that serves approximately 30,000 physicians and pharmaceutical partners with whole genome, exome, and reproductive health testing powered by its CentoCard platform and >1M-patient Biodatabank spanning 120+ countries.
- Company typePublic
- Founded2006
- HeadquartersRostock, Germany
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What Centogene does
Centogene GmbH is a Rostock-headquartered, multiomic genetic diagnostics company founded in 2006, publicly held through Centogene N.V. (Nasdaq:CNTG, now OTC:CNTGF) and operating under the ownership of Charme Capital Partners following the November 2024 sale of operating subsidiaries for EUR 8.7M. The company provides clinical genetic and multiomic testing—Whole Genome Sequencing (CentoGenome and CentoGenome Ultra-Fast), Whole Exome Sequencing (CentoXome), chromosomal microarray analysis (CentoArray), NIPT (CentoNIPT), carrier screening (CentoScreen), and customizable panels—anchored by its proprietary CentoCard dried blood spot sample collection platform and its >1M-patient Biodatabank spanning 120+ countries with over 70% non-European descent. Its MOx platform integrates genomic, transcriptomic, proteomic, and metabolomic data from a single sample, supported by an AI-assisted variant interpretation stack (CentoDx) and a free lifelong variant reclassification program.
The company operates three revenue streams. Clinical genetic testing services are billed per test to physicians, healthcare providers, and patients across approximately 30,000 active physicians and regional customer support hubs in APAC, Brazil, Canada, LATAM, Mexico, Spain & Portugal, UAE, and the US, with self-serve ordering through CentoPortal and specialized IVF ordering portals. Pharmaceutical partnerships generate revenue through clinical trial support, patient identification and stratification, sponsored testing programs (e.g., EFRONT, TRAMmoniTTR, ROPAD), and biodatabank access, with Agios disclosed as a named partner. Reproductive health services include PGT-A, CentoNIPT, and carrier screening for IVF clinics.
Centogene holds a dense regulatory stack—ISO 13485, CAP ISO 15189, CLIA (Rostock and Miami labs), ISO/IEC 27001, PCI DSS, and EU IVDR compliance—and reports over 350 peer-reviewed publications and 19,000+ genes in its testing portfolio. Following its Nasdaq delisting and PE-backed restructuring, the company is pursuing geographic expansion (Saudi Arabia JV with Lifera, Brazil acquisition) and product expansion (PGT-A, CentoPediatric, CentoScreen Exome), while historically operating at a revenue level around USD 50M with persistent operating losses.
Centogene firmographics
Firmographics- Name
- Centogene
- Legal name
- CENTOGENE GmbH
- Website
- https://centogene.com
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Centogene is a Rostock-based, PE-owned multiomic genetic diagnostics company that serves approximately 30,000 physicians and pharmaceutical partners with whole genome, exome, and reproductive health testing powered by its CentoCard platform and >1M-patient Biodatabank spanning 120+ countries.
- Ownership category
- akta.pro rank
Centogene industry classification
Industry- Product category
- Clinical Genetic Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
- akta.pro secondary industries
- Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
Keywords
Where Centogene is headquartered
LocationHeadquarters
- HQ city
- Rostock
- HQ country
- Germany
- HQ region
- Europe
Offices7 records
Markets served
Centogene business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Clinical Genetic Testing Services: Comprehensive genetic and multiomic testing services for physicians and patients including Whole Genome Sequencing (CentoGenome), Whole Exome Sequencing (CentoXome), NGS Panels, CentoArray, and specialized tests. Revenue generated through test fees billed to healthcare providers, insurance, and patients.
- Pharma Partnerships and Research Services: Partnering with pharmaceutical companies to accelerate drug discovery and development through patient identification and stratification, clinical trial support, and access to the biodatabank. Includes sponsored testing programs and registry studies (EFRONT, TRAMmoniTTR, ROPAD).
- Reproductive Health Services: Genetic testing services for reproductive health including PGT-A (Preimplantation Genetic Testing for Aneuploidy), carrier screening, CentoNIPT (Non-invasive prenatal testing), serving IVF clinics and reproductive genetics providers.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
Centogene product offering
Product offeringCore offering
CENTOGENE provides clinical genetic and multiomic diagnostic testing services, including whole genome sequencing (CentoGenome), whole exome sequencing (CentoXome), chromosomal microarray analysis (CentoArray), non-invasive prenatal testing (CentoNIPT), carrier screening, and preimplantation genetic testing (PGT-A), supported by its proprietary CENTOGENE Biodatabank of over 1 million patients and CentoCard dried blood spot sample collection technology. The company serves physicians, healthcare providers, pharmaceutical partners, and IVF clinics globally with rare and neurodegenerative disease diagnostics.
Product overview
CENTOGENE offers a comprehensive genetic and multiomic diagnostic portfolio centered around whole genome sequencing (CentoGenome), whole exome sequencing (CentoXome), and chromosomal microarray analysis (CentoArray). The portfolio includes specialized solutions such as CentoNIPT for prenatal testing, CentoScreen for carrier screening, and CentoCustom Panel for customizable testing. The MOx (Multiomic Solutions) platform integrates genomic, biochemical, and transcriptomic data combining WGS/WES with RNA sequencing and enzyme/metabolite analysis. Supporting infrastructure includes CentoCard for sample collection, CentoPortal for online ordering and report management, and CentoDx/CentoCloud for bioinformatics and variant interpretation. The company serves clinical diagnostics, pharmaceutical partners through registries and sponsored testing programs, and reproductive genetics markets.
Differentiator
Problem solved
Functional benefit
Brands
- CentoGenome: Whole Genome Sequencing solution - one of the world's most comprehensive tools for diagnosing rare and neurodegenerative diseases
- CentoXome
- CentoArray
- CentoCard
- CentoPortal
- CentoNIPT
- CentoMD
- CentoDx
- MOx
- CentoScreen
Products and services
- CentoGenome Whole Genome Sequencing (WGS) solution providing comprehensive genome coverage and diagnostic power for rare and neurodegenerative diseases, detecting nearly all variant types including SNVs, CNVs, repeat expansions, and mitochondrial variants.
- CentoGenome Ultra-Fast Rapid whole genome sequencing variant with results delivered in just 5 business days, designed for critically ill patients in ICU, neonatal, and emergency settings where rapid genetic diagnosis is crucial.
- CentoXome
Quantifiable outcome
- Diagnostic yield improvement through multiomic approach enabling integration of DNA, RNA, and biochemical data
- +3 more outcomes
Companies that use Centogene
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles4 records
Centogene technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature6 records
Centogene partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- BianalisicoreStrategic partnership announced at ESHG2025 in Milan, Italy. Bianalisi is an Italian diagnostic company serving as a channel partner for expanded distribution and market access in the Italian market.
- Critical Path Institute (C-Path)coreMemorandum of Understanding to enhance collaboration in lysosomal disease research and drug development. Aims to leverage combined expertise and data resources to accelerate therapeutic development for lysosomal storage diseases.
- LiferacoreJoint venture in Saudi Arabia with Lifera, a biopharmaceutical company owned by Saudi Arabia's Public Investment Fund. Aims to establish advanced genetic testing and bioinformatics facilities to enhance Saudi Arabia's biopharmaceutical sector. CENTOGENE contributes expertise and receives $30 million convertible loan, performance milestones, and royalties until 2033. Formation expected in late 2023.
Scale indicators10 records
Recent moves9 records
Expansion highlights6 records
Centogene competitors and assessment
Company assessmentDirect peers
- GeneDx (formerly Sema4): Specialist in rare disease and pediatric clinical genomics with a focus on whole exome/genome sequencing. Closest US-based direct competitor to Centogene's rare-disease and pediatric diagnostic franchise.
- NeoGenomics: Specialty oncology and rare disease clinical laboratory with both clinical and pharma services. Comparable business mix combining clinical diagnostics with pharma/biotech trial support.
- Invitae: Clinical genetic testing company offering comprehensive hereditary disease panels, exome, and genome sequencing. Directly comparable to Centogene in clinical genetic diagnostics, although Invitae has stronger US payer reach and underwent a 2024 restructuring that mirrors Centogene's challenges.
- Natera: Reproductive health (NIPT, PGT) and oncology genetic testing company. Direct overlap with Centogene's reproductive health segment (CentoNIPT, PGT-A, CentoScreen) and similar business model of high-volume specialty diagnostics.
- Ambry Genetics: Clinical genetics laboratory offering exome, genome, and panel testing across hereditary disease areas. Comparable in clinical genomic testing focus, particularly in rare disease and hereditary cancer.
- PreventionGenetics (part of Exact Sciences): Clinical genetic testing laboratory specializing in hereditary disease, reproductive, and whole genome/exome testing. Acquired by Exact Sciences in 2022, comparable in clinical rare-disease diagnostics scope and customer base.
- Myriad Genetics: Molecular diagnostics company with hereditary cancer, pharmacogenomic, and prenatal testing portfolios. Comparable in scale and clinical genomics business model, with strong pharma partnership capability.
Broad incumbents
- Quest Diagnostics: Major US clinical reference laboratory with growing specialty genetics and reproductive health offerings. Broad incumbent providing scaled alternative to Centogene for hospital systems and physician networks.
- Labcorp: Large diversified clinical reference laboratory offering broad specialty genetic and molecular diagnostic services. Overlaps with Centogene in clinical genomics but operates at substantially greater scale and breadth.
- Eurofins Scientific: European-headquartered clinical diagnostics and bioanalytical testing conglomerate. Provides comparable European footprint and specialty clinical lab services including reproductive genetics and rare disease testing.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Centogene social profiles
Digital presenceCentogene compliance and trust
Trust signalCompliance8 records
Centogene financial estimates
Financial estimateRevenue estimate
Valuation estimate
Centogene leadership team
Management profileNumber of profiles
Profiles10 records
Centogene subsidiaries and ownership
Company hierarchySubsidiaries2 records
Centogene funding detail
Funding detailFunding overview
Funding rounds6 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Centogene M&A and investment
M&A and investmentM&A1 record
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Centogene
What does Centogene do?
CENTOGENE provides clinical genetic and multiomic diagnostic testing services, including whole genome sequencing (CentoGenome), whole exome sequencing (CentoXome), chromosomal microarray analysis (CentoArray), non-invasive prenatal testing (CentoNIPT), carrier screening, and preimplantation genetic testing (PGT-A), supported by its proprietary CENTOGENE Biodatabank of over 1 million patients and CentoCard dried blood spot sample collection technology. The company serves physicians, healthcare providers, pharmaceutical partners, and IVF clinics globally with rare and neurodegenerative disease diagnostics.
Is Centogene a public or private company?
Centogene is a public company. It is classified as public and is currently operating.
When was Centogene founded?
Centogene was founded in 2006. It employs 501 to 1,000 people.
Where is Centogene based?
Centogene is headquartered in Rostock, Germany, in the Europe region.
How does Centogene make money?
Three revenue lines are on record. Clinical Genetic Testing Services are the primary driver. The others are pharma Partnerships and Research Services and reproductive Health Services.
Who are Centogene's main competitors?
Direct peers on record are GeneDx (formerly Sema4), NeoGenomics, Invitae, Natera, Ambry Genetics, PreventionGenetics (part of Exact Sciences) and Myriad Genetics. Broad incumbents are Quest Diagnostics, Labcorp and Eurofins Scientific.
Does Centogene have an API?
No public API is recorded for Centogene.
What industry is Centogene in?
Centogene's product category is Clinical Genetic Diagnostics. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HLAGAEAD, Genomics & Molecular Diagnostics (Trial Support). Its NAICS code is 621511 and its SIC code is 8071.